News

Results showed that the PAUL Glaucoma Implant is an effective glaucoma drainage device that provides effective IOP lowering, similar to that achieved with the Baerveldt Glaucoma Implant, but with lower rates of complications

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."

Investigators note a supply shortage led to use of half a dose for imaging purposes.

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

The organization is warning the public about the hazards of misusing contact lenses. Contact lens wearers also must take extra care when applying and removing eye cosmetics.

The effort will capture the real-life stories of patients and eye care professionals around the world.

A team of University of Rochester scientists develop computer models of patients’ eyes to identify the ideal IOLs and visual simulators for patients to experience how they will see with them.

According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

In cases where patients struggle with applying or tolerating eye drops, especially after previous selective laser trabeculoplasty (SLT) treatment, MicroPulse transscleral laser therapy (TLT) offers a practical solution.

Dr Barbara Parolini gives her guidance on navigating and managing the pathology in stages

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

Efficacy of treatment option is also confirmed in pediatric population in India.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

The investigators found that the corrected distance visual acuity (CDVA) in the amblyopic eye improved significantly in all patients regardless of age

Sequential customised therapeutic keratectomy (SCTK) improves visual quality by eliminating superficial corneal high order aberrations

We spoke with researchers and industry professionals at the 2023 ASRS meeting in Seattle, Washington. We asked them, "What do you wish patients knew about eye health?" Here's what Michael Ip, MD, Shawn Kavoussi, MD, and Megan Baldwin, PhD, had to say!

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

Preservative-free Iyuzeh, launched more than 10 years ago, currently is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.

Discover how advocacy can impact your clinical work and ultimately patient care.

Highlighting the benefits of Iridex's updated P3 Probe and Cyclo G6® Laser software for MicroPulse® transscleral laser therapy. The redesigned probe improves ergonomics and visibility, while the user-friendly software ensures precise, reproducible glaucoma treatments.